LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Summary
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants of concern (VOCs) have negatively affected therapeutic use of some authorized mAbs. Using a high-throughput B cell screening pipeline, we isolated LY-CoV1404 (bebtelovimab), a highly potent SARS-CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody. LY-CoV1404 potently neutralizes authentic SARS-CoV-2, B.1.1.7, B.1.351, and B.1.617.2. In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant. Structural analysis reveals that the contact residues of the LY-CoV1404 epitope are highly conserved, except for N439 and N501. The binding and neutralizing activity of LY-CoV1404 is unaffected by the most common mutations at these positions (N439K and N501Y). The broad and potent neutralization activity and the relatively conserved epitope suggest that LY-CoV1404 has the potential to be an effective therapeutic agent to treat all known variants.
Top-30
Citations by journals
2
4
6
8
10
12
|
|
Cell Reports
11 publications, 3.81%
|
|
iScience
9 publications, 3.11%
|
|
Viruses
7 publications, 2.42%
|
|
Nature Communications
6 publications, 2.08%
|
|
Cell Host and Microbe
6 publications, 2.08%
|
|
International Journal of Molecular Sciences
5 publications, 1.73%
|
|
Nature
5 publications, 1.73%
|
|
Frontiers in Immunology
4 publications, 1.38%
|
|
PLoS Pathogens
4 publications, 1.38%
|
|
Cell
4 publications, 1.38%
|
|
Cell Reports Medicine
4 publications, 1.38%
|
|
Emerging Microbes and Infections
4 publications, 1.38%
|
|
Science immunology
3 publications, 1.04%
|
|
Vaccines
3 publications, 1.04%
|
|
Antibodies
3 publications, 1.04%
|
|
Signal Transduction and Targeted Therapy
3 publications, 1.04%
|
|
Scientific Reports
3 publications, 1.04%
|
|
Science Translational Medicine
3 publications, 1.04%
|
|
The Lancet Infectious Diseases
3 publications, 1.04%
|
|
Journal of Infectious Diseases
3 publications, 1.04%
|
|
Journal of Virology
3 publications, 1.04%
|
|
Science
3 publications, 1.04%
|
|
Proceedings of the National Academy of Sciences of the United States of America
3 publications, 1.04%
|
|
Antibody Therapeutics
3 publications, 1.04%
|
|
Virology Journal
2 publications, 0.69%
|
|
Nature Immunology
2 publications, 0.69%
|
|
Pathogens
2 publications, 0.69%
|
|
Pharmaceuticals
2 publications, 0.69%
|
|
Life
2 publications, 0.69%
|
|
2
4
6
8
10
12
|
Citations by publishers
10
20
30
40
50
60
70
80
|
|
Elsevier
75 publications, 25.95%
|
|
Cold Spring Harbor Laboratory
49 publications, 16.96%
|
|
Springer Nature
44 publications, 15.22%
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
32 publications, 11.07%
|
|
American Association for the Advancement of Science (AAAS)
11 publications, 3.81%
|
|
Frontiers Media S.A.
10 publications, 3.46%
|
|
Oxford University Press
10 publications, 3.46%
|
|
Taylor & Francis
7 publications, 2.42%
|
|
Public Library of Science (PLoS)
6 publications, 2.08%
|
|
Wiley
6 publications, 2.08%
|
|
American Society for Microbiology
6 publications, 2.08%
|
|
American Chemical Society (ACS)
4 publications, 1.38%
|
|
Proceedings of the National Academy of Sciences (PNAS)
3 publications, 1.04%
|
|
Bentham Science
2 publications, 0.69%
|
|
Wolters Kluwer Health
2 publications, 0.69%
|
|
American Society of Hematology
2 publications, 0.69%
|
|
Mary Ann Liebert
1 publication, 0.35%
|
|
American College of Allergy, Asthma, & Immunology
1 publication, 0.35%
|
|
KeAi Communications Co.
1 publication, 0.35%
|
|
Thieme
1 publication, 0.35%
|
|
Rockefeller University Press
1 publication, 0.35%
|
|
Royal Society of Chemistry (RSC)
1 publication, 0.35%
|
|
PagePress
1 publication, 0.35%
|
|
IGI Global
1 publication, 0.35%
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.35%
|
|
10
20
30
40
50
60
70
80
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.